These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 15689298)
1. Levothyroxine and FDA bioequivalence ratings. Fox GN J Fam Pract; 2005 Feb; 54(2):179. PubMed ID: 15689298 [No Abstract] [Full Text] [Related]
2. Levothyroxine dosage and the limitations of current bioequivalence standards. Hennessey JV Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):474-5. PubMed ID: 16957756 [No Abstract] [Full Text] [Related]
3. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study. Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789 [TBL] [Abstract][Full Text] [Related]
4. Generic substitution: issues for problematic drugs. Henderson JD; Esham RH South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935 [TBL] [Abstract][Full Text] [Related]
6. L-T4 bioequivalence and hormone replacement studies via feedback control simulations. Eisenberg M; Samuels M; DiStefano JJ Thyroid; 2006 Dec; 16(12):1279-92. PubMed ID: 17199439 [TBL] [Abstract][Full Text] [Related]
7. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs. Patsner B Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473 [No Abstract] [Full Text] [Related]
8. Levothyroxine: therapeutic use and regulatory issues related to bioequivalence. Wartofsky L Expert Opin Pharmacother; 2002 Jun; 3(6):727-32. PubMed ID: 12036412 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of human thyroid disease. Klein I; Danzi S Thyroid; 2003 Dec; 13(12):1127-32. PubMed ID: 14751033 [TBL] [Abstract][Full Text] [Related]
10. Unithroid becomes first levothyroxine tablet to gain FDA approval. Traynor K Am J Health Syst Pharm; 2000 Oct; 57(19):1736-7. PubMed ID: 11030022 [No Abstract] [Full Text] [Related]
11. Bioequivalence of generic preparations of levothyroxine. Toft A Clin Endocrinol (Oxf); 2009 Oct; 71(4):603; author reply 603-4. PubMed ID: 19508682 [No Abstract] [Full Text] [Related]
12. Bioavailability and bioequivalence requirements: abbreviated applications. Final Rule. Food and Drug Administration, HHS Fed Regist; 2002 Dec; 67(244):77668-75. PubMed ID: 12492102 [TBL] [Abstract][Full Text] [Related]
13. Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium. ; ; Thyroid; 2004 Jul; 14(7):486. PubMed ID: 15307934 [No Abstract] [Full Text] [Related]
15. Bioequivalence of levothyroxine preparations for treatment of hypothyroidism. Spigelman MK JAMA; 1997 Apr; 277(15):1199-200. PubMed ID: 9103337 [No Abstract] [Full Text] [Related]
16. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Blakesley V; Awni W; Locke C; Ludden T; Granneman GR; Braverman LE Thyroid; 2004 Mar; 14(3):191-200. PubMed ID: 15072701 [TBL] [Abstract][Full Text] [Related]
17. Generic drugs revisited. Med Lett Drugs Ther; 2009 Oct; 51(1323):81-2. PubMed ID: 19838144 [No Abstract] [Full Text] [Related]
18. Bioequivalence of thyroid preparations: the final word? Gibaldi M AAPS J; 2005; 7(1):E59-60. PubMed ID: 16493834 [No Abstract] [Full Text] [Related]
19. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Dietrich JW; Gieselbrecht K; Holl RW; Boehm BO Horm Metab Res; 2006 Jan; 38(1):57-9. PubMed ID: 16477543 [No Abstract] [Full Text] [Related]
20. Requirements for submission of bioequivalence data; final rule. Final rule. Food and Drug Administration, HHS Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]